证券代码：300645 证券简称：正元智慧 公告编号：2025-060 债券代码：123196 债券简称：正元转 02 正元智慧集团股份有限公司 《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》等相关法津、法规和规范性文件 的规定。监事会同意本次《关于使用部分闲置募集资金暂时补充流动资金的议案》。 《正元智慧集团股份有限公司关于使用部分闲置募集资金暂时补充流动资金 的公告》详见公司于 2025 年 7 月 9 日在巨潮资讯网（http://www.cninfo.com.cn）上 披露的公告。 表决结果：全体监事以 3 票同意、0 票反对、0 票弃权。同意票数占本次监事 会有效表决票数的 100%，表决通过。 经审议，监事会认为：本次变更部分募集资金用途，符合公司实际经营情况和 业务发展的需要，有利于提高募集资金使用效率，不会对公司目前的正常生产经营 产生重大不利影响，符合中国证监会、深圳证券交易所关于上市公司募集资金管理 的相关规定，监事会同意本次《关于变更部分募集资金用途的议案》。 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没 ...

Core Viewpoint - The company, Shandong Heda Group Co., Ltd., is changing part of the fundraising purpose from the issuance of convertible bonds to permanently supplement working capital, which is deemed necessary for its operational needs and will not adversely affect other investment projects [1][5][9]. Fundraising Overview - The company was approved to issue 6 million convertible bonds with a total fundraising amount of 600 million RMB, netting approximately 592.75 million RMB after deducting issuance costs [1][2]. - As of June 30, 2025, the company has utilized approximately 457.47 million RMB of the raised funds, leaving a balance of about 135.76 million RMB [2][4]. Fund Usage Details - The remaining funds include 120 million RMB that was temporarily used to supplement working capital and has since been returned [2][4]. - The company plans to terminate the investment project for "Hershey's annual production of 15 billion plant capsules and intelligent three-dimensional warehouse upgrade project," which was initially planned for an investment of 181.68 million RMB [5][6]. Reasons for Fund Usage Change - The decision to halt the aforementioned project is influenced by changes in the international situation and market environment, which have affected the project's feasibility [5][6]. - The remaining funds will be used for daily operations and business development, enhancing the efficiency of fund usage and alleviating financial pressure [5][8]. Impact of Fund Usage Change - The change in fund usage is considered a prudent adjustment that aligns with the company's operational needs and will not negatively impact other investment projects [5][8]. - The company aims to optimize resource allocation and reduce financial costs, thereby improving operational efficiency and safeguarding the interests of the company and its investors [8][9]. Approval Process - The board of directors and the supervisory board have approved the change in fund usage, which will be submitted for further approval at the shareholders' meeting and the bondholders' meeting [8][9].

证券代码：002810 证券简称：山东赫达 公告编号：2025-046 山东赫达集团股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 山东赫达集团股份有限公司（以下简称"公司"）已于 2025 年 7 月 2 日以电话、现场送达方式向公司全体监事发出了关于召开第九 届监事会第十五次会议的通知（以下简称"本次会议"或"会议"）。本 次会议于 2025 年 7 月 4 日在公司会议室召开，应出席监事 3 人，实 际出席监事 3 人，会议由监事会主席杨涛先生召集并主持，本次会 议以现场会议形式召开。本次会议召集和召开程序符合《中华人民 共和国公司法》 《深圳证券交易所股票上市规则》和《公司章程》的 有关规定。 二、监事会会议审议情况 经全体与会监事认真审议，作出决议如下： 表决结果：3 票赞成，0 票反对，0 票弃权。 监事会认为：公司变更部分募集资金用途用于永久补充流动资 金，是公司根据发展规划作出的审慎决策，有利于提高募集资金使 用效率，不存在损害公司及股东利益的情形。 该议案尚需提交公司股东大会审议。 证券代码：002810 ...

Summary of Key Points Core Viewpoint The company, Opcon Vision Technology Co., Ltd., is changing part of its fundraising purpose to acquire a 75% stake in Suqian Shangyue Qicheng Hospital Management Co., Ltd. This strategic move aims to enhance operational efficiency and align with the company's long-term development goals. Group 1: Fundraising and Financial Overview - The actual amount raised from the stock issuance was RMB 149,406.89 million after deducting issuance costs, with funds received in June 2022 [2][3]. - As of December 31, 2024, the company has utilized RMB 39,677.38 million of the raised funds, with a remaining balance of RMB 12,726.07 million after accounting for interest and investment income [3][4]. - The company plans to redirect RMB 23,373.00 million from the "Community Optical Service Terminal Construction Project" to fund the acquisition of Shangyue Qicheng [4][5]. Group 2: Acquisition Details - The total investment for acquiring a 75% stake in Shangyue Qicheng is RMB 33,390.00 million, with RMB 23,373.00 million sourced from the raised funds and RMB 10,017.00 million from the company's own funds [5][9]. - The acquisition aligns with the company's dual-driven development strategy of "full optical products + all-age optical services," enhancing its market presence in Yunnan Province [7][8]. - Shangyue Qicheng has established a comprehensive operational system and possesses strong brand recognition and profitability potential in the region [7][12]. Group 3: Financial Performance and Projections - Shangyue Qicheng's audited financial data shows total assets of RMB 11,073.59 million and net assets of RMB 6,151.34 million as of the latest report [14]. - The company has committed to achieving specific net profit targets from 2025 to 2029, with a minimum of RMB 3,900 million in 2025 [24]. - Future revenue growth is projected based on the expansion of service offerings and market penetration strategies, with a focus on medical services and optical products [21][22].

Summary of Key Points Core Viewpoint The company, Kailaiying Pharmaceutical Group (Tianjin) Co., Ltd., is undergoing changes in the use of raised funds, including new investment projects, adjustments in investment amounts, and delays in project timelines, to enhance operational efficiency and align with market opportunities. Group 1: Fundraising Overview - The company raised a total of RMB 2,277,875,164.30 from a non-public stock issuance, with a net amount of RMB 2,274,960,656.06 after deducting issuance costs [1][2] - The funds are stored in a dedicated account, regulated by a tripartite agreement among the company, the sponsor, and the bank [2] Group 2: Fund Usage Status - As of June 30, 2025, the company has allocated funds to various projects, including the expansion of its life sciences platform and the construction of a biopharmaceutical R&D base [3][4] - The total investment for the projects is RMB 228,070.62 million, with cumulative investments of RMB 163,909.18 million [4] Group 3: Changes in Fund Usage - The company has proposed to change the use of funds for the "Taixing Project" and redirect remaining funds to new projects, including a chemical macromolecule project and a high-end formulation project [5][6] - The investment amount for the Taixing Project will be reduced by RMB 400 million, with the remaining funds allocated to new projects [6][11] Group 4: New Investment Projects - A new project, the "Chemical Macromolecule Integration Project," will receive RMB 47,367.72 million from the remaining funds, with a total investment of RMB 50,800.00 million [11][12] - The project aims to enhance the company's capacity in the CDMO field and is expected to take 48 months to complete [12][14] Group 5: Financial Performance - The company's total assets as of December 31, 2024, were RMB 3,073,514,644.17, with total liabilities of RMB 2,080,120,300.01 and net assets of RMB 993,394,344.16 [13] - The company reported a revenue of RMB 1,597,172,881.12 and a net profit of RMB 52,163,151.56 for the same period [13] Group 6: Strategic Implications - The changes in fund usage are aligned with the company's long-term strategic planning and are expected to improve operational efficiency and competitiveness [19][20] - The company aims to leverage market trends and enhance its capabilities in innovative drug development, particularly in the chemical macromolecule sector [15][16]

中信建投证券股份有限公司 关于北京航天长峰股份有限公司变更募集资金用途 并将剩余募集资金永久性补充流动资金的核查意见 中信建投证券股份有限公司（以下简称"中信建投"或"保荐人"）作为北 京航天长峰股份有限公司（以下简称"航天长峰"或"公司"）2022 年非公开发 行股票的保荐人，根据《证券发行上市保荐业务管理办法》《上市公司募集资金 监管规则》 《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管 指引第 1 号——规范运作》等有关法律法规的规定，对航天长峰变更募集资金用 途并将剩余募集资金永久性补充流动资金的事项进行了认真、审慎核查，并发表 了核查意见，具体核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会下发的《关于核准北京航天长峰股份有限公司非 公开发行股票的批复》 （证监许可〔2022〕2375 号）核准，公司以非公开发行的 方式发行 27,752,474 股人民币普通股（A 股），发行价格为 11.72 元/股，募集资 金 总 额 为 人 民 币 325,258,995.28 元 ， 扣 除 保 荐 承 销 等 有 关 发 行 费 用 人 民 币 司专用账户，募集资金到位情况 ...

证券代码：600855 证券简称：航天长峰 公告编号：2025-025 北京航天长峰股份有限公司 十届十五次监事会会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 详见《北京航天长峰股份有限公司关于变更募集资金用途并将 剩余募集资金永久性补充流动资金的公告》 （公告编号：2025-027）。 此议案表决结果如下：3 票赞成，0 票弃权，0 票反对。 特此公告。 北京航天长峰股份有限公司 监事会 北京航天长峰股份有限公司（以下简称"航天长峰"或"公司"） 于 2025 年 6 月 27 日以书面形式发出通知，并于 2025 年 7 月 1 日下 午在航天长峰大厦八层 822 会议室以现场方式召开了十届十五次监 事会会议。会议由监事会主席黄亿兵先生主持，会议应到监事 3 人， 实到监事 3 人。本次监事会的召开程序符合《中华人民共和国公司法》 和《公司章程》的有关规定。与会监事认真审议了本次会议的议案， 形成了如下决议： 一、审议通过了公司关于变更募集资金用途并将剩余募集资金 永久性补充流动资金的议案。 监事会出具审核 ...

证券代码：300505 证券简称：川金诺 公告编号：2025-040 昆明川金诺化工股份有限公司 关于对外投资建设川金诺（埃及）苏伊士磷化工项目暨 拟变更募集资金用途项目的进展公告 近日，公司取得了云南省发展和改革委员会出具的《境外投资项目备案 通知书》（云发改外资备案〔2025〕0031 号）、云南省商务厅核发的《企业 境外投资证书》（境外投资证第 N5300202500053 号）。 三、备查文件 特此公告。 昆明川金诺化工股份有限公司 董 事 会 一、对外投资概述 昆明川金诺化工股份有限公司（以下简称"公司"）分别于 2025 年 4 月 17 日、2025 年 5 月 8 日召开第五届董事会第十四次会议、2025 年第一次临时股 东大会审议通过了《关于对外投资建设川金诺（埃及）苏伊士磷化工项目的议案》， 同意公司在埃及建设年产 80 万吨硫磺制酸、30 万吨工业湿法粗磷酸、15 万吨 具体内容详见公司于 2025 年 4 月 18 日在中国证监会指定的创业板信息披露平 台巨潮资讯网上发布的《关于对外投资建设川金诺（埃及）苏伊士磷化工项目的 公告》（公告编号：2025-024）。 会第十二次会议，审议通 ...

Group 1 - The company announced a change in the use of part of the raised funds and a delay in investment projects, specifically reducing the investment amount for the "Konjac Deep Processing Intelligent Manufacturing Production Line Expansion and Renovation Project" from 101.05 million yuan to 91.36 million yuan, reallocating 26 million yuan for the construction of the Hydrophilic Colloid Industrial Park Renovation and Digital Transformation Project (Phase I) [2] - The "Konjac Deep Processing Intelligent Manufacturing Production Line Expansion and Renovation Project" was initially planned in 2022 based on market conditions and company circumstances, and the company has adhered to regulations regarding the use of raised funds while ensuring the project's smooth implementation [2] - As of May 31, 2025, the basic construction of the project, including civil works and equipment, has been completed [2] Group 2 - The company plans to extend the "Konjac Deep Processing Intelligent Manufacturing Production Line Expansion and Renovation Project" deadline to December 2025, utilizing working capital during the extension period to purchase raw materials needed for production [3] - The total planned investment for the "Hydrophilic Colloid Industrial Park Renovation and Digital Transformation Project (Phase I)" is 56.04 million yuan, with 26 million yuan sourced from the original raised funds, while the remaining amount will be financed through the company's own or self-raised funds [3] - The completion of the project is expected to enhance the company's production capacity for hydrophilic colloids, meet market demand, and improve the company's market competitiveness and profitability, thereby expanding future development opportunities [3]

Group 1 - The company, O-Film, announced on June 27 that it will hold the eighth (temporary) meeting of the sixth board of directors on June 27, 2025, to review the proposal for changing part of the fundraising purpose and adding new investment projects [2] - The company agreed to change the use of part of the raised funds, reallocating 200 million yuan from the "Hefei Jingchao Optical Technology Co., Ltd. Optical Lens and Lens Production Line Project" and 353.7568 million yuan from the "High-Pixel Optical Lens Construction Project" to the new project "High-Precision Optical Lens Production Line Upgrade and Expansion Project" [2] - The total amount of funds involved in this change is 553.7568 million yuan, which accounts for 15.76% of the net amount raised from the company's non-public stock issuance [2] Group 2 - The company’s revenue composition for the year 2024 is entirely from the manufacturing of optical and optoelectronic components, accounting for 100.0% [3]